Lv Haitao's research group from the Institute of Systems Biomedicine, Shanghai Jiao Tong University, together with the teams from Xi'an Jiaotong University and the University of Macau, published a review of the frontiers of treatment strategies for IBD

Recently, Haitao Lv's research group from the Institute of Systems Biomedicine, Shanghai Jiaotong University, in collaboration with teams from Xi'an Jiaotong University and the University of Macau, published a review of the frontiers of IBD treatment strategies in the famous pharmacological journal "Pharmacological Research"

Inflammatory bowel disease (IBD) is a complex disease induced by multiple factors, and its incidence has gradually increased significantly, seriously affecting the health of a wide range of people

Functional Metabolomics is a brand-new frontier interdisciplinary scientific strategy.

In recent years, Lyu Haitao's research group from the Institute of Systems Biomedicine, Shanghai Jiao Tong University, Xi'an Jiaotong University, and the University of Macau have collaborated to develop therapeutic discovery research for IBD based on functional metabolomics strategies, that is, based on the co-metabolism of gut microbiota and host functions, Elucidation of new targets and new mechanisms of action of berberine and dihydrogenase in the prevention and treatment of pancreatic cancer chemotherapy complications (side effects) complicated colitis, one of which was selected as a highly cited paper in ESI, which provides information for the treatment of IBD and the development of new drugs Target basis and molecular basis of drug candidates for a new functional metabolic dimension

Recently, based on the good cooperation foundation, three scientific research teams jointly published a high-level frontier review "Emerging pharmacotherapy for inflammatory bowel diseases"

Original link: https:// class="Article-source form-horizontal">